Article

Alcon reports findings of two moxifloxacin studies

Alcon Laboratories announced the results of two clinical studies on itsfourth-generation fluoroquinolone moxifloxacin (Vigamox). The results werepresented in a Monday morning poster session.

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
4DMT releases positive topline interim data from Part 1 of the SPECTRA clinical trial
January 15th 2025

4DMT releases positive topline interim data from Part 1 of the SPECTRA clinical trial

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ashvattha Therapeutics secures $50M in financing to advance clinical trials
January 15th 2025

Ashvattha Therapeutics secures $50M in financing to advance clinical trials

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union
January 14th 2025

Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
January 14th 2025

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

© 2025 MJH Life Sciences

All rights reserved.